Collaborative research with Dr. Nathanael Gray of DFCI is part of our effort to develop new medicine.Bae Jae Hyun, PhD
We are developing "first-in-class" and "best-in-class"
global innovative new drugs.Hwangeun Choi, PhD
The in silico molecular design platform with virtual screening allows Voronoi to quickly discover hit compounds, and accelerate predicting efficacy and pharmacological value.Kim Namdoo, PhD

Scientific Advisory Board

Scientific Advisory Board

Leadership

Leadership

Daekwon Kim / CEO, R&D

Korea Health Industry Development Institute
Seoul National University, Pharmacy, M.S.
Seoul National University, Pharmacy, B.S.

Hyuntai Kim / CEO, Management

Seoul National University Business School, MBA
Seoul National University Business School, B.A.

Younkyoung Lee / Clinical Development

Boehringer Ingelheim Korea, Clinical Development Director
Seoul National University, Public Health, M.S.
Seoul National University, Nursing, B.S.

Dr. Sunghwan Kim /  Biochemistry

Polus, Development Director
Catholic University, Research Professor
Massachusetts Institute of Technology(MIT), Post Doc

Dr. Jaehyun Bae / Open Innovation

Yale University(Professor Joseph Schlessinger), Research Professor
Max-Planck Institute for Biochemistry (Professor Robert Huber), Ph.D.

Dr. Sunhwa Lee / Early-phase Discovery

University of Southern California / Seoul National University, Research Professor
Harvard Medical School, Instructor
Boston University, Ph.D.

Sangjin Woo / Finance

Seoul National University Business School, MBA
Seoul National University Business School, B.A.

Ikhwan Sung / Operations

McKinsey & Co. / The Rohatyn Group
Wharton School, MBA
Seoul National University Business School, B.A.

Sangjin Lee / Human Resources

Bank of Korea
Seoul National University, Economics, B.A.

Jaeyoung Ahn / Business Development(Advanced markets)

UC Berkeley, MFE
Seoul National University, Engineering, B.S.

Junil Park / Business Development(China and Emerging markets)

Mirae Asset, PEF
Peking University, B.A.

Giho Kwon / Legal Affairs

46th Judicial Examination
Seoul National University, Law, LL.M.
Seoul National University, Law, LL.B.

Noori Seo / External Relations

Sungkyunkwan University Law School, LL.M.
Seoul National University, Politics, B.A.

Hyunseok Kim / Artificial Intelligence

Hongik University, Adjunct Professor
Yonsei University, Engineering, M.S.

Dr.Namdoo Kim / CEO of Voronoi Bio

National New Drug Development Center
Yonsei University, Ph.D.

Dr. Jungbeom Son / CTO of Voronoi Bio

Sogang University, Ph.D.

Dr. Hwangeun Choi / CEO of B2S Bio

“Small-Molecule Inhibitors of LRRK2”(2017), Advances in Neurobiology vol. 14, Co-author
Dana Farber Cancer Institute, Staff Scientist

Dr. Nathanael Gray /  Co-Founder of B2S Bio

Professor at Harvard Medical School(Dana Farber Cancer Institute)
Genomics Institute of the Novartis Research Foundation Kinase Inhibitor Group Leader

Dr. Eunhwa Ko / CTO of B2S Bio

Yale University, Post Doc
Texas A&M University, Ph.D.